IP Library › Granted Patent US 12,365,711
Granted Patent B2
US 12,365,711 · App. 18/297,491 · Granted Jul 22, 2025

TGFβ signal convertor

Inventor: Benjamin Boyerinas (Brookline, MA)
Assignee: Regeneron Pharmaceuticals, Inc.
C07K14/495A61K40/11A61K40/22A61K40/31A61K40/32A61K40/4204A61K40/421A61K40/4217A61K40/4229A61K40/4269A61P35/00C07K14/5434C07K14/7051A61K38/00A61K38/1793C07K14/70575C07K2319/02C07K2319/03C07K2319/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,365,711
App. No.
18/297,491
Granted
Jul 22, 2025
Kind
B2
Abstract

The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

Claims (40)

1. A polynucleotide encoding a fusion polypeptide comprising:

(a) a first polypeptide comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO: 27;

(b) a viral self-cleaving 2A peptide; and

(c) a second polypeptide comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO: 26;

wherein the fusion polypeptide increases STAT4 and/or STAT5 phosphorylation when expressed in a cell in the presence of extracellular TGFβ1.

2. The polynucleotide of claim 1 , wherein the viral self-cleaving 2A polypeptide is a porcine teschovirus-1 (PTV-1) (P2A) peptide.

3. The polynucleotide of claim 1 , wherein the fusion polypeptide further comprises (i) an engineered antigen receptor and (ii) a second polypeptide cleavage signal or viral self-cleaving 2A polypeptide.

4. A lentiviral vector comprising the polynucleotide of claim 1 .

5. A cell comprising the polynucleotide of claim 1 .

6. The cell of claim 5 , wherein the cell is:

(a) a hematopoietic cell;

(b) a T cell;

(c) a CD3 + , CD4 + , and/or CD8 + cell;

(d) an immune effector cell;

(e) a cytotoxic T lymphocyte (CTL), a tumor infiltrating lymphocyte (TIL), or a helper T cell; or

(f) a natural killer (NK) cell or natural killer T (NKT) cell.

7. The cell of claim 6 , wherein the cell is a T cell.

8. The cell of claim 6 , wherein the cell is an immune effector cell.

9. The cell of claim 6 , wherein the cell is a cytotoxic T lymphocyte (CTL).

10. A composition comprising the cell of claim 6 .

11. The polynucleotide of claim 1 , wherein the first polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 27.

12. The polynucleotide of claim 1 , wherein the second polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 26.

13. The polynucleotide of claim 1 , wherein the first polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 27 and the second polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 26.

14. A polynucleotide encoding a fusion polypeptide comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO: 28, wherein the fusion polypeptide increases STAT4 and/or STAT5 phosphorylation when expressed in a cell in the presence of extracellular TGFβ1.

15. The polynucleotide of claim 14 , wherein the viral self-cleaving 2A polypeptide is a porcine teschovirus-1 (PTV-1) (P2A) peptide.

16. The polynucleotide of claim 14 , wherein the fusion polypeptide further comprises (i) an engineered antigen receptor and (ii) a second polypeptide cleavage signal or viral self-cleaving 2A polypeptide.

17. A lentiviral vector comprising the polynucleotide of claim 14 .

18. A cell comprising the polynucleotide of claim 14 .

19. The cell of claim 18 , wherein the cell is:

(a) a hematopoietic cell;

(b) a T cell;

(c) a CD3 + , CD4 + , and/or CD8 + cell;

(d) an immune effector cell;

(e) a cytotoxic T lymphocyte (CTL), a tumor infiltrating lymphocyte (TIL), or a helper T cell; or

(f) a natural killer (NK) cell or natural killer T (NKT) cell.

20. The cell of claim 19 , wherein the cell is a T cell.

21. The cell of claim 19 , wherein the cell is an immune effector cell.

22. The cell of claim 19 , wherein the cell is a cytotoxic T lymphocyte (CTL).

23. A composition comprising the cell of claim 19 .

24. The polynucleotide of claim 14 , wherein the fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 28.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2024
From: 2SEVENTY BIO, INC.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 067626/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2023
From: BOYERINAS, BENJAMIN
To: 2SEVENTY BIO, INC.
Reel/Frame 064469/0371 →
Continuity (4)
Continuation 16348450
Provisional Application 62423565 · Nov 17, 2016
Provisional Application 62467496 · Mar 6, 2017
Related Publication 20230364141A1 · Nov 16, 2023
References Cited (95)
US 4751180A · Cousens et al. · 1988 [cited by applicant]
US 4935233A · Bell et al. · 1990 [cited by applicant]
US 5994136A · Naldini et al. · 1999 [cited by applicant]
US 6013516A · Verma et al. · 2000 [cited by applicant]
US 6682907B1 · Charneau et al. · 2004 [cited by applicant]
US 6692736B2 · Yu et al. · 2004 [cited by applicant]
US 11654158B2 · Boyerinas · 2023 [cited by applicant]
US 20090222936A1 · Richmond et al. · 2009 [cited by applicant]
US 20150266973A1 · Jarjour et al. · 2015 [cited by applicant]
US 20160075755A1 · Valdes et al. · 2016 [cited by applicant]
US 20170036091A1 · Hooper et al. · 2017 [cited by applicant]
US 20170360913A1 · Zhao et al. · 2017 [cited by applicant]
US 20180024479A1 · Yamada et al. · 2018 [cited by applicant]
US 20180244797A1 · Pulé et al. · 2018 [cited by applicant]
US 20190350974A1 · Boyerinas · 2019 [cited by applicant]
US 20230044580A1 · Mann et al. · 2023 [cited by applicant]
US 20230159612A1 · Ellinger et al. · 2023 [cited by applicant]
JP 2009514541A · 2009 [cited by applicant]
JP 2016520302A · 2016 [cited by applicant]
WO WO2007054250A1 · 2007 [cited by applicant]
WO WO2012006635A1 · 2012 [cited by applicant]
WO WO2012138858A1 · 2012 [cited by applicant]
WO WO2014172584A1 · 2014 [cited by applicant]
WO WO2015017214A1 · 2015 [cited by applicant]
WO WO2016122738A1 · 2016 [cited by applicant]
WO WO2016164089A2 · 2016 [cited by applicant]
WO WO2017029512A1 · 2017 [cited by applicant]
WO WO2018094244A1 · 2018 [cited by applicant]
WO WO2020193767A1 · 2020 [cited by applicant]
WO WO2020227483A1 · 2020 [cited by applicant]
Extended European Search Report for EP Application No. 23216595.1 dated May 29, 2024. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP20/58779 dated Sep. 28, 2021. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2017/062358 dated May 21, 2019. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2020/031796 dated Nov. 2, 2021. [cited by applicant]
Kim et al., “High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice”, PLoS ONE, vol. 6 (4) e18556, (2011). [cited by applicant]
Wang et al., “Detection of RNA Interference (RNAi) Mediated mRNA Cleavage in Fresh Injected Tumor Tissue from Patients in a Phase I Trial of pbi-shRNA (TM) Lipoplex Targeting Stathmin-1”, Molecular Therapy. vol. 22. Nat… [cited by applicant]
Watanabe et al., “Conferring CAR T Cells With Resistance to TGFbeta1 Using a Signal Converter,” Molecular Therapy, May 2014, vol. 22, Supplement 1, pp. S298-S299. [cited by applicant]
Zhu et al., “A Pivotal Role for the Transmembrane Domain in Transforming Growth Factor-b Receptor Activation”, The Journal of Biological Chemistry, vol. 274, No. 17, Issue of Apr. 23, p. 11773-11781, (1999). [cited by applicant]
Asao et al., “Cutting Edge: The Common y-Chain Is an Indispensable Subunit of the IL-21 Receptor Complex,” The Journal of Immunology, 2001, 167, 1-5. [cited by applicant]
Bird et al. “Single-chain antigen-binding proteins.” Science (1988); 242.4877: 423-427. [cited by applicant]
Challita et al., “Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells.” J Virol. (1995); 69(2)… [cited by applicant]
Chaudhary et al. “A rapid method of cloning functional variable-region antibody genes in [cited by applicant]
Cheung et al., “Accessory Protein-Like Is Essential for IL-18-Mediated Signaling,” The Journal of Immunology, 2005, 174, 5351-5357. [cited by applicant]
Clever, J. et al., “RNA Secondary Structure and Binding Sites for gag Gene Products in the 5′ Packaging Signal of Human Immunodeficiency Virus Type 1.” J. of Virology (1995); 69(4): 21012109. [cited by applicant]
Cooper et al. “T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B-lineage leukemia effect.” Blood (2003); 101.4: 1637-1644. [cited by applicant]
Cullen et al., “Regulatory Pathways Governing HIV-1 Replication”, Cell (1989); 58: 423-426. [cited by applicant]
Cullen, “Human Immunodeficiency Virus as a Prototypic Complex Retrovirus”, Journal of Virology (1991); 65(3): 1053-1056. [cited by applicant]
De Felipe et al., “Targeting of proteins derived from self-processing polyproteins containing multiple signal sequences.” Traffic (2004); 5.8: 616-626. [cited by applicant]
Desjarlais et al., “Length-encoded multiplex binding site determination: application to zinc finger proteins,” Proceedings of the National Academy of Sciences (1994); 91.23: 11099-11103. [cited by applicant]
Desjarlais et al., “Use of a zinc-finger consensus sequence framework and specificity rules to design specific DNA binding proteins.” Proceedings of the National Academy of Sciences (1993); 90.6: 2256-2260. [cited by applicant]
Duke et al., Sequence and structural elements that contribute to efficient encephalomyocarditis virus RNA translation, J Virol. Mar. 1992;66(3):1602-9. [cited by applicant]
Dull et al., “A third-generation lentivirus vector with a conditional packaging system”, Journal of Virology (1998); 72(11): 8463-8671. [cited by applicant]
Extended European Search Report for EP Application No. 17872043.9 mailed on Mar. 30, 2020, 12 pages. [cited by applicant]
Fukuo, “Interleukin 2, IL-2,” The Journal of Japan Atherosclerosis Society, 1996, 24, 4-5, 155-161. [cited by applicant]
Huang et al., “Role of the hepatitis B virus posttranscriptional regulatory element in export of intronless transcripts,” Molecular and Cellular Biology (1995); 15(7): 3864-3869. [cited by applicant]
Huez et al., “Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA,” Mol Cell Biol. Nov. 1998;18(11):6178-90. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/062358, dated Apr. 3, 2018, 16 pages. [cited by applicant]
International Search Report and Written Opinion mailed on Oct. 14, 2020, for International Application No. PCT/US2020/031796, 16 pages. [cited by applicant]
Irion et al., “Identification and targeting of the ROSA26 locus in human embryonic stem cells”, Nat Biotechnol. (2007); 25(12):1477-1482. [cited by applicant]
Jackson, et al., “Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond”, RNA. (1995); 1(10): 985-1000. [cited by applicant]
Jackson, et al., “The novel mechanism of initiation of picornavirus RNA translation”, Trends Biochem Sci. (1990); 15(12): 477-483. [cited by applicant]
Jena et al., “Driving CAR-Based T-Cell Therapy to Success,” Curr Hematol Malig Rep. Mar. 2014; 9(1):50-56. [cited by applicant]
Kim et al. “Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain.” Proceedings of the National Academy of Sciences (1996); 93.3: 1156-1160. [cited by applicant]
Kutner et al., “Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors”, Nature Protocols (2009); 4: 495-505. [cited by applicant]
Kutner et al., “Simplified production and concentration of HIV-1-based lentiviral vectors using HYPERFlask vessels and anion exchange membrane chromatography”, BMC Biotechnol. (2009); 9:10. p. 1-7. [cited by applicant]
Liu et al. “Design of polydactyl zinc-finger proteins for unique addressing within complex genomes.” Proceedings of the National Academy of Sciences (1997); 94.11: 5525-5530. [cited by applicant]
Liu et al. (2016). “A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors,” Cancer Res. 76:1578-1590. [cited by applicant]
Liu et al., “HnRNP L binds a cis-acting RNA sequence element that enables intron-dependent gene expression,” Genes & Dev. (1995); 9: 1766-1780. [cited by applicant]
Maratea et al., “Deletion and fusion analysis of the phage phi X174 lysis gene E,” Gene. 1985;40(1):39-46. [cited by applicant]
Murphy et al., “Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion protein,” Proc Natl Acad Sci U S A. Nov. 1986;83(21):8258-6… [cited by applicant]
Naldini et al., “Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector”, Proc Natl Acad Sci USA (1996); 93(21): 11382-11388. [cited by applicant]
Naldini et al., “In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector”, Science (1996); 272(5259): 263-267. [cited by applicant]
Naldini, “Lentiviruses as gene transfer agents for delivery to non-dividing cells”, Curr Opin Biotechnol. (1998); 5: 457-463. [cited by applicant]
Office Action for JP Application No. 2019-526305 dated Jul. 4, 2022, 10 pages. [cited by applicant]
Office Action for JP Application No. 2019-526305, dated Oct. 4, 2021, 9 pages. [cited by applicant]
Ozaki et al., “Cytokine and Cytokine Receptor Pleiotropy and Redundancy,” The Journal of Biological Chemistry, Aug. 16, 2002, 277,33, 29355-29358. [cited by applicant]
Patel et al., “Impact of chimeric immune receptor extracellular protein domains on T cell function.” Gene Ther (1999); 6(3): 412-419. [cited by applicant]
Pomerantz et al., “Analysis of homeodomain function by structure-based design of a transcription factor,” Proc Natl Acad Sci USA Oct. 10, 1995;92(21):9752-6. [cited by applicant]
Pomerantz et al., “Structure-based design of transcription factors.” Science (1995); 267.5194: 93-96. [cited by applicant]
Ryan et al., “Virus-encoded proteinases of the picornavirus super-group.” J Gen Virol. (1997); 78 (Pt 4): 699-723. [cited by applicant]
Shi et al., “Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects,” Molecular Cancer 2014, 13:219, 8 pages. [cited by applicant]
Supplementary European Search Report for EP Application No. 20802730.0 dated Jul. 11, 2023, 6 pages. [cited by applicant]
Szymczak et al. “Correction of multi-gene deficiency in vivo using a single‘self-cleaving’2A peptide-based retroviral vector.” Nature Biotechnology (2004); 22.5: 589-594. [cited by applicant]
Takara Bio Inc., Idenshidonyujikken handobukku (handbook of gene transfer experimentation), Nov. 2015, p. 1-10. [cited by applicant]
Third Party Submission Under 37 CFR 1.290 submitted on Sep. 1, 2020, for U.S. Appl. No. 16/348,450, 9 pages. [cited by applicant]
Wang et al., “Detection of RNA Interference (RNAi) Mediated mRNA Cleavage in Fresh Injected Tumor Tissue from Patients in a Phase I Trial of pbi-shRNATM Lipoplex Targeting Stathmin-1,” Molecular Therapy, May 2014, vol. … [cited by applicant]
Yang et al., “Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition”, Gene Therapy, Nov. 2008, vol. 15, No. 21, pp. 1411-1423. [cited by applicant]
Zennou et al., “HIV-1 genome nuclear import is mediated by a central DNA flap,” Cell. Apr. 14, 2000;101(2):173-85. [cited by applicant]
Zhang et al., “Engineering CAR-T cells,” Biomarker Research (2017) 5:22, 6 pages. [cited by applicant]
Zufferey et al., “Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo”, Nat Biotechnol. (1997), 15(9): 871-875. [cited by applicant]
Zufferey et al., “Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors.” J Virol. (1999); 73(4): 2886-2892. [cited by applicant]
Boyerinas et al., “A novel TGF-[beta]-/IL-12R signal conversion platform that protects CAR T cells from TGF-[beta]-mediated immune suppression and concurrently amplifies effector function.” Cancer Research 77.13_Supplem… [cited by applicant]
Dotto et al., “Squamous cell cancers: a unified perspective on biology and genetics.” Cancer Cell 29(5) (2016): 622-637. [cited by applicant]
Presky et al., “A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits.” Proc Natl Acad Sci US A Nov. 26, 1996;93(24):14002-7. [cited by applicant]
Yang et al., “T-cell lineage determination.” Immunol Rev. Nov. 2010;238(1): 12-22. [cited by applicant]
Cited By (1)
US 12,590,136